Author:
Rha S.Y.,Wyrwicz L.S.,Weber P.E.Y.,Bai Y.,Ryu M.H.,Lee J.,Rivera F.,Alves G.V.,Garrido M.,Shiu K-K.,Fernández M. González,Li J.,Lowery M.,Cil T.,Cruz F.J.S.M.,Qin S.,Yin L.,Bordia S.,Bhagia P.,Oh D-Y.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025
2. Immunotherapeutic strategies in gastroesophageal tumors;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025
3. Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer;ESMO Gastrointestinal Oncology;2024-09
4. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial;Gastric Cancer;2024-08-20
5. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial;LANCET GASTROENTEROL;2024